https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51574 Wed 28 Feb 2024 15:29:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49615 Wed 14 Jun 2023 18:25:34 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46029 Wed 09 Nov 2022 15:52:02 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42916 Wed 07 Sep 2022 10:15:26 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42967 Wed 07 Feb 2024 16:43:21 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41960 Tue 30 Apr 2024 08:49:39 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54492 Tue 27 Feb 2024 15:12:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48332 Tue 14 Mar 2023 17:01:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33514 Tue 13 Nov 2018 13:55:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52096 Thu 28 Sep 2023 14:35:16 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42349 Thu 04 Apr 2024 11:57:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42697 Thu 01 Sep 2022 09:44:54 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42693 Thu 01 Sep 2022 09:27:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29250 Sat 24 Mar 2018 07:36:46 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39038 Mon 29 Jan 2024 17:52:28 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37705 2.5 cfu/cm2 to indicate hygiene failure. Results: There were low levels of microbial contamination in the unit for baseline; DHP; and no DHP phases: 2.2% (95% CI 0.7-5.4%) vs 7.7% (95% CI 4.3-13.0%) vs 6% (95% CI 3.2-10.4%) hygiene failures, respectively. Significant reduction in ACCs did not occur when the DHP was operating compared with baseline and control phases. Conclusion: Further work is needed to determine whether continuous DHP technology has a role in decontamination for healthcare settings.]]> Mon 22 Mar 2021 10:00:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40996 Mon 08 Aug 2022 14:43:16 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39056 Cryptococcus neoformans and Cryptococcus gattii are yeasts responsible for invasive infection, primarily pulmonary and neurological. Their clinical epidemiology has been previously described in an Australian national study, but this included no data from the Hunter region, where we anecdotally noted a high incidence of infection. We aimed to describe the epidemiology, management and outcomes of cryptococcal disease in the Hunter region and to compare this with previous Australian data. Methods: We searched our laboratory database for positive cryptococcal antigen and culture results from January 2003-December 2016. We extracted demographic factors, risk factors, clinical presentation, treatment and outcomes from medical records. We used the 2010 census-derived estimated resident population to calculate population-based incidences. Results: Over a 13-year period, 107 patients had either a positive culture or a positive cryptococcal antigen with a compatible clinical syndrome. Of these, 46 (42.2%) were C. neoformans, 28 (25.7%) C. gattii, and 33 (30.3%) antigen only. The crude incidence (per million with 95% CI) for all disease was 9.5, and for culture proven disease was 2.5 for C. gattii and 4.1 for C. neoformans. Geospatial mapping by species revealed no evident cluster. Of the 63 patients where detailed information was available, around half were immunocompromised (3 [15%] for C. gattii and 25 [81%] for C. neoformans, p < 0.001). Complications were common, including visual loss (11 cases, 17.7%) and hearing loss (5 cases, 8%). Adverse outcomes at one year (death or neurological sequelae) occurred in 42%, and was significantly more likely (OR = 5.2, 95% CI 1.4-18.8) in those with raised intracranial pressure at baseline. Adverse outcomes were no more common in those treated with lower doses of liposomal amphotericin (≤150 mg/day, 5/10) than those treated with the recommended dose of 3-5 mg/kg (≥150 mg; 13/27). Conclusion: Although a rare disease, cryptococcosis is more common in the Hunter region than in other parts of Australia, and long-term sequelae are serious and common.]]> Mon 02 May 2022 15:13:36 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51899 Fri 22 Sep 2023 09:30:06 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36760 Fri 03 Jul 2020 11:25:41 AEST ]]>